Prostate Cancer VL

Office Based Therapeutics - Focal Therapy - Under a Paradigm of Certainty LUGPA 2022 Presentation- Fernando Bianco

Details
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Fernando Bianco presented on office-based therapeutics - focal therapy: under a paradigm of certainty during optimizing Ambulatory Surgery Centers (ASC) utilization. Biography: Fernando J. Bianco, MD, Investor in-Chief, Urological Research Network, Miami, FL, Professor of Urology, NOVA Southeastern University, Hollywood,...

Battling Prostate Cancer with Optimism and Perseverance - Hugo Mercado

Details
Hugo Mercado recounts his journey with prostate cancer. Initially unaware of his diagnosis, Hugo discovered his condition indirectly, as doctors didn't explicitly inform him. Despite his family's concern, particularly his wife's hidden distress, Hugo remained strong and healthy, never having been seriously ill before. An active lifestyle, including competitive sports and cycling, served as his the...

The Prostate Cancer Foundation VA Health Initiatives, Executing Precision Oncology within the VA - Matthew Rettig & Isla Garraway

Details
Matthew Rettig and Isla Garraway discuss the progress and aspirations of the Veterans Administration (VA) prostate cancer program, established through a Memorandum of Understanding with the Prostate Cancer Foundation. The program has expanded from six to 13 Centers of Excellence, with the VA committing $50 million to this initiative. Dr. Rettig emphasizes the program's focus on precision oncology,...

Exploring the Potential of Lutetium PSMA in High-Risk Localized Prostate Cancer: The LuTectomy Trial - Renu Eapen

Details
Renu Eapen, a recipient of the PCF Young Investigator Award, details her groundbreaking project on early use of Lutetium PSMA for high-risk localized prostate cancer. The two-cohort clinical trial involves administering Lutetium PSMA upfront, followed by radical prostatectomy. An integral part of the study is the translational work, analyzing changes in the tumor microenvironment in response to Lu...

Addressing Prostate Cancer Health Disparities - Leanne Woods-Burnham

Details
Leanne Woods-Burnham discusses her 2020 Young Investigator Award project with the Prostate Cancer Foundation, focusing on prostate cancer disparities, especially among black men. Her research looks at HER2 expression and its connection to West African ancestry. She explains that HER2 is correlated with this ancestry, rather than self-reported race. The project involves RNA sequencing on tumor tiss...

Longitudinal Patient Sampling and Immune Profiling in Oligometastatic Prostate Cancer - Sophia Kamran

Details
Alicia Morgans speaks with Sophia Kamran, who won the Young Investigator Award in 2021. Dr. Kamran shares her research into the potentially beneficial role of radiation in treating oligometastatic prostate cancer, a field where much remains unknown. She is particularly focused on defining the disease more biologically, while also examining the complex interaction of radiation with the immune syste...

Scaling Up Point-of-Care Genetic Testing in the VA: A Nurse-Led Initiative - Kara Maxwell

Details
Kara Maxwell shares insights about the groundbreaking work she and her team have been undertaking in germline genetic testing. Supported by PCF funds, they aim to bolster genetic testing programs for patients within the VA system and beyond. Notably, Dr. Maxwell praises the contributions of her colleague, Dr. Lisa Aiello, a skilled PhD-trained nurse, who has been instrumental in establishing a poi...

Exploring the Nuances of the PRONOUNCE Trial - Celestia Higano

Details
Alicia Morgans and Tia Higano discuss the PRONOUNCE trial, which evaluates the effects of degarelix and leuprolide on cardiovascular events in high-risk prostate cancer patients. Dr. Higano offers insightful explanations concerning the trial's methodology, highlighting its initial slow accrual and early cessation due to a futility analysis. However, she points out that the trial's results, which s...

PROCLAIM Study Reveals Impact of Germline Genetic Testing on Prostate Cancer Clinical Decisions - Neal Shore

Details
Neal Shore shares insights from his presentation about the PROCLAIM trial - a study examining the impact of germline genetic testing on prostate cancer clinical decisions. Dr. Shore underscores the importance of expanding testing beyond traditional criteria, given the prevalence of pathogenic germline variants among both qualifying and non-qualifying patients under NCCN criteria. Notably, the tria...

Navigating the Challenges of Somatic Mutation Testing in Prostate Cancer - Joaquin Mateo

Details
Alicia Morgans engages with Joaquin Mateo to discuss the clinically relevant challenges and approaches to somatic mutation testing in advanced prostate cancer patients. They address the difficulties in obtaining adequate tissue for testing, the concordance between different testing mechanisms, and the balance between ideal plans and clinical feasibility. Dr. Mateo emphasizes the importance of unde...